Angiogenic MicroRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes

Anna Zampetaki, Peter Willeit, Simon Jonathan Burr, Xiaoke Yin, Sarah Raye Langley, Stefan Kiechl, Ronald Klein, Peter Rossing, Nishi Chaturvedi, Manuel Mayr

Research output: Contribution to journalArticlepeer-review

104 Citations (Scopus)
242 Downloads (Pure)


Circulating microRNAs (miRNAs) have emerged as novel biomarkers of diabetes. The present study focuses on the role of circulating miRNAs in patients with type 1 diabetes and their association with diabetic retinopathy. A total of 29 miRNAs were quantified in serum samples (n=300) using a nested case-control study design in two prospective cohorts of the Diabetic Retinopathy Candesartan Trial (DIRECT programme): PROTECT-1 and PREVENT-1. The PREVENT-1 trial included patients without retinopathy at baseline; the PROTECT-1 trial included patients with non-proliferative retinopathy at baseline. Two miRNAs previously implicated in angiogenesis, miR-27b and miR-320a, were associated with incidence and with progression of retinopathy: the odds ratio per standard deviation higher miR-27b was 0.57 (95%CI: 0.40, 0.82; P=0.002) in PREVENT-1, 0.78 (0.57, 1.07; P=0.124) in PROTECT-1, and 0.67 (0.50, 0.92; P=0.012) combined. The respective odds ratios for miR-320a were 1.57 (1.07, 2.31; P=0.020), 1.43 (1.05, 1.94; P=0.021), and 1.48 (1.17, 1.88; P=0.001). Proteomics analyses in endothelial cells returned the anti-angiogenic protein thrombospondin-1 as a common target of both miRNAs. Our study identifies two angiogenic miRNAs, miR-320a and miR-27b, as potential biomarkers for diabetic retinopathy.
Original languageEnglish
Pages (from-to)216-227
Number of pages11
Issue number1
Early online date22 Sept 2015
Publication statusPublished - 1 Jan 2016


Dive into the research topics of 'Angiogenic MicroRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes'. Together they form a unique fingerprint.

Cite this